Sanofi builds focus on rare blood disorders and cancers Some of the most serious unmet patient needs today are in the field of hematology. Rare blood ...
Awful News “Bayer laying off 10 percent of its workforce”
Bayer laying off 10 percent of its workforce In a bid to reboot its sluggish performance, the pharmaceutical and agribusiness giant has announced cuts...
Samsung to showcase latest medical imaging & artificial intelligence for radiologists at RSNA 2018
Samsung to showcase latest medical imaging & artificial intelligence for radiologists at RSNA 2018 Samsung Electronics, a leader in medical imagin...
Do you know that “New study reveals probiotics do not help children with intestinal infections”
Do you know that “New study reveals probiotics do not help children with intestinal infections” Probiotics are a multibillion-dollar indus...
Eyes of CJD patients show evidence of prions
Eyes of CJD patients show evidence of prions National Institutes of Health scientists and their colleagues have found evidence of the infectious agent...
Patients save around Rs. 15,000 crores under Government’s initiative of ensuring ‘Affordable, Quality Medicines for All’: Shri Mansukh Mandaviya
Patients save around Rs. 15,000 crores under Government’s initiative of ensuring ‘Affordable, Quality Medicines for All’: Shri Mansukh Mandaviya...
Boston Scientific to acquire BTG for US$ 4.2 billion
Boston Scientific to acquire BTG for US$ 4.2 billion Boston Scientific has reached an agreement on the terms of a recommended offer to acquire BTG plc...
Merck and Pfizer provide update on avelumab in platinum-resistant/refractory ovarian cancer
Merck and Pfizer provide update on avelumab in platinum-resistant/refractory ovarian cancer Merck and Pfizer Inc. (NYSE: PFE) today announced that the...
MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa
MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa MorphoSys AG (FSE: MOR; P...
Seattle Genetics Submits Supplemental Biologics License Application in Frontline Treatment of Peripheral T-Cell Lymphomas
Seattle Genetics Submits Supplemental Biologics License Application in Frontline Treatment of Peripheral T-Cell Lymphomas Seattle Genetics, Inc. anno...